Healthcare -
Biotechnology - NASDAQ - US
$ 1.9317
1.61 %
$ 5.02 M
Market Cap
-1.11
P/E
1. INTRINSIC VALUE
Balance Sheet
VivoSim Labs, Inc.
| Current Assets | 12.1 M |
| Cash & Short-Term Investments | 11.3 M |
| Receivables | 30 K |
| Other Current Assets | 789 K |
| Non-Current Assets | 2.52 M |
| Long-Term Investments | 0 |
| PP&E | 1.29 M |
| Other Non-Current Assets | 1.23 M |
| Current Liabilities | 3.74 M |
| Accounts Payable | 1.64 M |
| Short-Term Debt | 521 K |
| Other Current Liabilities | 1.57 M |
| Non-Current Liabilities | 421 K |
| Long-Term Debt | 421 K |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
VivoSim Labs, Inc.
| Revenue | 144 K |
| Cost Of Revenue | 5 K |
| Gross Profit | 139 K |
| Operating Expenses | 12.8 M |
| Operating Income | -12.6 M |
| Other Expenses | -10.1 M |
| Net Income | -2.49 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
VivoSim Labs, Inc.
| Net Income | -2.49 M |
| Depreciation & Amortization | 266 K |
| Capital Expenditures | -13 K |
| Stock-Based Compensation | 532 K |
| Change in Working Capital | 1.04 M |
| Others | -8.29 M |
| Free Cash Flow | -9.47 M |
Wall Street Analysts Price Targets
VivoSim Labs, Inc.
VIVS has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
VIVS does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
VivoSim Labs, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
I Missed The Quantum Rally - I Won't Miss The Next One
Here's the next batch of weird science stocks that have market darling potential. I'm tracking five meme-worthy, deep science sectors: brain-computer interfaces, CRISPR/gene editing, organoids, programmable cell therapy, and room-temperature superconductors. Monitor each sector's stocks poised to soar if a major tech player announces a breakthrough.
seekingalpha.com
- 2 months ago
VivoSim's NAMKind™ Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference
SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”) announced today that its NAMkind™ platform for intestinal efficacy prediction was recognized with a blue ribbon “Poster of Distinction” award at the Digestive Disease Week Conference (San Diego, CA, May 2-6, 2025). The work describes developing a robust, multicellular in vitro model that closely mirrors human intestinal biology, paving the way for safer and more effective therapies for inflammatory bowel disease (IBD).
globenewswire.com
- 2 months ago
VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market
SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company”) announced that it has emerged from stealth mode to dramatically impact drug discovery and development.
globenewswire.com
- 3 months ago
8. Profile
Summary
VivoSim Labs, Inc. VIVS
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 5.02 M
Dividend Yield
0.00%
Description
VivoSim Labs, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company's lead candidate is FXR314, which is phase 2/3clinical trial for indication of inflammatory bowel disease with a clinical focus on ulcerative colitis; and completed phase 1 clinical trial for the indication of liver fibrosis with a clinical focus steatohepatitis. Organovo Holdings, Inc. has research collaborations with Yale School of Medicine, Knight Cancer Institute at Oregon Health & Science University, and the University of Virginia for research of NovoGen Bioprinters. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. The company was incorporated in 2007 and is headquartered in San Diego, California.
Contact
11555 Sorrento Valley Road, San Diego, CA, 92121
https://www.organovo.com
IPO
Date
Feb. 14, 2012
Employees
14
Officers
Mr. Keith E. Murphy
Executive Chairman & Corporate Secretary
Dr. Curtis M. Tyree Ph.D.
Senior Vice President of Strategy & Business Development
Mr. Norman Staskey
President, Chief Financial Officer & Principal Financial Officer